Cell entry by enveloped viruses: Redox considerations for HIV and SARS-coronavirus

Antioxidants and Redox Signaling

Volumn 9, Issue 8, 2007, Pages 1009-1034

  Fenouillet, Emmanuel ^a   Barbouche, Rym ^a   Jones, Ian M ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; DISULFIDE; ISOMERASE; OXIDOREDUCTASE; THIOL;

CATALYSIS; CONFORMATIONAL TRANSITION; ENVIRONMENTAL STRESS; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; MEMBRANE FUSION; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BINDING; REACTION ANALYSIS; REVIEW; SARS CORONAVIRUS; VIRION; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS GENOME;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD4; DISULFIDES; HIV; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PROTEIN STRUCTURE, TERTIARY; SARS VIRUS;

SARS CORONAVIRUS;

EID: 34447502257     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1639     Document Type: Review

References (150)

1. Abell BA and Brown DT. Sindbis virus membrane fusion is mediated by reduction of glycoprotein disulfide bridges at the cell surface. J Virol 67: 5496-5501, 1993.
2. Akagi S, Yamamoto A, Yoshimori T, Masaki R, Ogawa R, and Tashiro Y. Localization of protein disulfide isomerase on plasma membranes in rat exocrine pancreatic cells. J Histochem Cytochem 36: 1069-1074, 1988.
3. Anthony RP, Paredes AM, and Brown DT. Disulfide bonds are essential for the stability of the Sindbis virus envelope. Virology 190: 330-336, 1992.
4. Avril LE, Di Martino-Ferrer M, Pignede G, Seman M, and Gauthier F. Identification of the U937 membrane-associated proteinase interacting with the V3 loop of HIV-1 gp120 as cathepsin G. FEBS Lett 345: 81-86, 1994.
5. Babcock GJ, Esshaki DJ, Thomas WD Jr, and Ambrosino DM. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 78: 4552-4560, 2004.
6. Barbara G, Scozzafava A, Mastrolorenzo A, and Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11: 1805-1804, 2005.
7. Barbouche R, Feyfant E, Belhaj B, and Fenouillet E. Pharmacophore determination of a gp120 C terminal-derived anti-HIV peptide construct interfering with membrane fusion suggesting that processing of the gp120 C terminus is a prelude to fusion. AIDS Res Hum Retroviruses 18: 201-206, 2002.
8. Barbouche R, Lortat-Jacob H, Jones IM, and Fenouillet E. Glycosaminoglycans and protein disulfide isomerase-mediated reduction of HIV Env. Mol Pharm 67: 1111-1118, 2005.
9. Barbouche R, Miquelis R, Jones IM, and Fenouillet E. Protein disulfide isomerase-mediated reduction of two disulfide bonds of HIV Env gp120 occurs post CXCR4 binding and is required for fusion. J Biol Chem 278: 3131-3136, 2003.
10. Batinic D and Robey FA. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem 267: 6664-6671, 1992.
11. Benham AM. Oxidative protein folding: an update. Antioxid Redox Signal 7: 835-838, 2005.
12. Beniac DR, Andonov A, Grudeski E, and Booth TF. Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol 13: 751-752, 2006.
13. Bennett TA, Edwards BS, Sklar LA, and Rogelj S. Sulfhydryl regulation of L-selectin shedding: phenylarsine oxide promotes activation-independent L-selectin shedding from leukocytes. J Immunol 164: 4120-4129, 2000.
14. Berger EA, Murphy PM, and Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700, 1999.
15. Berridge MV and Tan AS. High-capacity redox control at the plasma membrane of mammalian cells: trans-membrane, cell surface, and serum NADH-oxidases. Antioxid Redox Signal 2: 231-242, 2000.
16. Bhattacharya J, Peters PJ, and Clapham PR. CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS 17(S4): S35-S43, 2003.
17. Billington J, Hickling TP, Munro GH, Halai C, Chung R, Dodson GG, Daniels RS. Stability of a receptor-binding active HIV-1 recombinant gp140 trimer conferred by inter-monomer disulphide-bonding of the V3-loop: differential effects of protein disulphide isomerase on CD4 and co-receptor binding. J Virol. Epub ahead of print, 2007
18. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, and Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 101: 6641-6646, 2004.
19. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, and Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (Lond) 382: 829-833, 1996.
20. Bosch BJ, Martina BE, Van Der Zee R, Lepault J, Haijema BJ, Versluis C, Heck AJ, De Groot R, Osterhaus AD, and Rottier PJ. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat derived peptides. Proc Natl Acad Sci U S A 101: 8455-8460, 2004.
21. Bosch BJ, van der Zee R, Haan CA, and Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77: 8801-8811, 2003.
22. Briz V, Poveda E, and Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 57: 619-612, 2006.
23. Burgess JK, Hotchkiss KA, Suter C, Dudman NP, Szollosi J, Chesterman CN, Chong BH, and Hogg PJ. Physical proximity and functional association of glycoprotein 1balpha and protein disulfide isomerase on the platelet plasma membrane. J Biol Chem 275: 9758-9766, 2000.
24. Cabibbo A, Pagani M, Fabbri M, Rocchi M, Farmery MR, Bulleid NJ, and Sitia R. ERO1-L, a human protein that favors disulfide bond formation in the endoplasmic reticulum. J Biol Chem 275: 4827-4833, 2000.
25. Cai H, Wang CC, and Tsou CL. Chaperone-like activity of protein disulfide isomerase in the refolding of a protein with no disulfide bonds. J Biol Chem 269: 24550-24552, 1994.
26. Calatroni A, Vinci R, and Ferlazzo AM. Characteristics of the interactions between acid glycosaminoglycans and proteins in normal human plasma as revealed by the behaviour of the protein-polysaccharide complexes in ultrafiltration and chromatographic procedures. Clin Chim Acta 206: 167-180, 1992.
27. Callebaut C, Krust B, Jacotot E, and Hovanessian AG. T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. Science 262: 2045-2050, 1993.
28. Carr CM, Chaudhry C, and Kim PS. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci U S A 94: 14306-14313, 1997.
29. Chakraborti S, Prabakaran P, Xiao X, and Dimitrov DS. The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2: 73, 2005.
30. Chan DC, Fass D, Berger JM, and Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273, 1997.
31. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, and Harrison SC. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (Lond) 433: 834-841, 2005.
32. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, Cheng VC, Tsui WH, Hung IF, Lee TS, Guan Y, Peiris JS, and Yuen KY. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 31: 69-75, 2004.
33. Chen J, Lee KH, Steinhauer DA, Stevens DJ, Skehel JJ, and Wiley DC. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95: 409-417, 1998.
34. Chinese SMEC. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303: 1666-1669, 2004.
35. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, and Sodroski J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148, 1996.
36. Clements GJ, Price-Jones MJ, Stephens PE, Sutton C, Schulz TF, Clapham PR, McKeating JA, McClure MO, Thomson S, Marsh M, and Moore JP. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses 7: 3-16, 1991.
37. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P. Identification of RANTES, MIP-1a, and MIP-1b as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811-1815, 1995.
38. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185: 621-628, 1997.
39. Couet J, de Bernard S, Loosfelt H, Saunier B, Milgrom E, and Misrahi M. Cell surface protein disulfide-isomerase is involved in the shedding of human thyrotropin receptor ectodomain. Biochemistry 35: 14800-14805, 1996.
40. Creighton TE, Zapun A, and Darby NJ. Mechanisms and catalysts of disulfide bond formation in proteins. Trends Biotechnol 13: 18-23, 1995.
41. Darby NJ, Penka E, and Vincentelli R. The multi-domain structure of protein disulfide isomerase is essential for high catalytic activity. J Mol Biol 276: 239-247, 1998.
42. Dauer B. Protease inhibitors: the current status. J HIV Ther 10: 72-74, 2005.
43. Debnath AK. Prospects and strategies for the discovery and development of small-molecule inhibitors of six-helix bundle formation in class 1 viral fusion proteins. Curr Opin lnvestig Drugs 7: 118-127, 2006.
44. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, and Shaw GM. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201: 1407-1419, 2005.
45. De Groot AS. How the SARS vaccine effort can learn from HIV: speeding towards the future, learning from the past. Vaccine 21:4095-4104. 2003
46. Dimitrov DS. Cell biology of virus entry. Cell 101: 697-702, 2000.
47. Doms RW and Peiper SC. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235: 179-190, 1997.
48. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, and Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976, 2003.
49. Eckert DM and Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810, 2001.
50. Edman JC, Ellis L, Blacher RW, Roth RA, and Rutter WJ Sequence of protein disulphide isomerase and implications of its relationship to thioredoxin. Nature (Lond) 317: 267-270, 1985.
51. Einfeld D. Maturation and assembly of retroviral glycoproteins. Curr Top Microbiol 214: 133-176, 1996.
52. Ellgaard L and Ruddock LW. The human protein disulphide isomerase family: substrate interactions and functional properties EMBO Rep 6: 28-32, 2005.
53. Essex DW, Li M, Miller A, and Feinman RD. Protein disulfide isomerase and sulfhydryl-dependent pathways in platelet activation. Biochemistry 40: 6070-6075, 2001.
54. Este JA. Virus entry as target for anti-HIV intervention. Curr Med Chem 10: 1617-1632, 2003.
55. Feener EP, Shen WC, and Ryser HJ. Cleavage of disulfide bonds in endocytosed macromolecules: a processing not associated with lysosomes or endosomes. J Biol Chem 265: 18780-18786, 1990.
56. Fenouillet E, Gluckman JC, and Jones IM. Functions of HIV envelope glycans. Trends Biochem Sci 19: 65-70, 1994.
57. Fenouillet E, Barbouche R, Courageot J, and Miquelis R. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding. J Infect Dis 183: 744-752, 2001.
58. Fenouillet E, Barbouche R, and Jones IM. HIV Env reduction post-receptor binding: a new target for AIDS treatment. Blood 104: 296, 2004.
59. Ferrari DM and Soling HD. The protein disulphide-isomerase family: unravelling a string of folds. Biochem J 339: 1-10, 1999.
60. Finnegan CM, Berg W, Lewis GK, and DeVico AL. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J Virol 75: 11096-11105, 2001.
61. Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, Peiris M, Lim W, Stohr K, and Osterhaus AD. Aetiology: Koch's postulates fulfilled for SARS virus. Nature (Lond) 423: 240, 2003.
62. Freedman RB, Klappa P, and Ruddock LW. Protein disulfide isomerases exploit synergy between catalytic and specific binding domains. EMBO Rep 3: 136-140, 2002.
63. Gallagher TM. Murine coronavirus membrane fusion is blocked by modification of thiols buried within the spike protein. J Virol 70: 4683-4690, 1996.
64. Gallina A, Hanley TM, Mandel R, Trahey M, Broder CC, Viglianti GA, and Ryser HJ. Inhibitors of protein disulfide isomerase (PDI) prevent cleavage of disulfide bonds in receptor-bound gp120 and prevent HIV-1 entry. J Biol Chem 277: 50579-50588, 2002.
65. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, and Blumenthal R. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 1614: 36-50, 2003.
66. Gallo SA, Puri A, and Blumenthal R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry 40: 12231-12236, 2001.
67. Ghezzi P. Oxidoreduction of protein thiols in redox regulation. Biochem Soc Trans 33: 1378-1381, 2005.
68. Gramberg T, Hofmann H, Moller P, Lalor PF, Marzi A, Geier M, Krumbiegel M, Winkler T, Kirchhoff F, Adams DH, Becker S, Munch J, and Pohlmann S. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology 340: 224-236, 2005.
69. Gros C, Linder M, and Wengler G. Analyses of disulfides present in the rubella virus E1 glycoprotein. Virology 230: 179-186, 1997.
70. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS, and Poon LL. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278, 2003.
71. Gupta-Bansal R, Frederickson RCA, and Brunden KR. Proteoglycan-mediated inhibition of A beta proteolysis: a potential cause of senile plaque accumulation. J Biol Chem 270: 18666-18671, 1995.
72. Harrop HA, Coombe DR, and Rider CC. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS 8: 183-192, 1994.
73. Harrop HA and Rider CC. Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Glycobiology 8: 131-137, 1998.
74. Hartley O and Offord RE. Engineering chemokines to develop optimized HIV inhibitors. Curr Protein Pept Sci 6: 207-219, 2005.
75. He Y, Lu H, Siddiqui P, Zhou Y, and Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174: 4908-4915, 2005.
76. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, and Weiss CD Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 77: 1666-1671, 2003.
77. Hensel G, Abmann V, and Kern HF. Hormonal regulation of protein disulfide isomerase and chaperone synthesis in the rat exocrine pancreas. Eur J Cell Biol 63: 208-218, 1994.
78. Hirota K, Nakamura H, Masutani H, and Yodoi J. Thioredoxin superfamily and thioredoxin-inducing agents. Ann N Y Acad Sci 957: 189-199, 2002.
79. Ho HT, Fan L, Nowicka-Sans B, McAuliffe B, Li CB, Yamanaka G, Zhou N, Fang H, Dicker I, Dalterio R, Gong YF, Wang T, Yin Z, Ueda Y, Matiskella J, Kadow J, Clapham P, Robinson J, Colonno R, and Lin PF. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol 80: 4017-4025, 2006.
80. Hofmann H, Hattermann K, Marzi A, Gramberg T, Geier M, Krumbiegel M, Kuate S, Uberla K, Niedrig M, and Pohlmann S. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 78: 6134-6142, 2004.
81. Hofmann H, Pyre K, van der Hoek L, Geier M, Berkhout B, and Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 102:7988-7993, 2005.
82. Hogg PJ, Hotchkiss KA, Jimenez BM, Stathakis P, and Chesterman CN. Interaction of platelet-derived growth factor with thrombospondin 1: dependence on the disulfide-bond arrangement in thrombospondin 1. Biochem J 326: 709-716, 1997.
83. Hogg PJ. Disulfide bonds as switches for protein function. Trends Biochem Sci 28: 210-214, 2003.
84. Holmes KV. SARS-associated coronavirus. N Engl J Med 348: 1948-1951, 2003.
85. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 264: 13963-13966, 1989.
86. Hotchkiss KA, Matthias LJ, and Hogg PJ. Exposure of the cryptic Arg-Gly-Asp sequence in thrombospondin-1 by protein disulfide isomerase. Biochim Biophys Acta 1388: 478-488, 1998.
87. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, and Kwong PD. Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028, 2005.
88. Huang EM, Detwiler TC, Milev Y, and Essex DW. Thiol-disulfide isomerization in thrombospondin: effects of conformation and protein disulfide isomerase. Blood 89: 3205-3212, 1997.
89. Hunter E. In: Viral entry and receptors. In: Retroviruses, edited by Coffin JM, Hughes SH, Varmus HE. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1997, pp. 71-119.
90. Ito M, Baba M, Sato A, Pauwels R, de Clercq E, and Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antivir Res 7: 361-367, 1987.
91. Jain S, McGinnes LW, and Morrison TG. Thiol/disulfide exchange is required for membrane fusion directed by the Newcastle disease virus fusion protein. J Virol 81: 2328-2233, 2007.
92. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, Thomas WD Jr, Thackray LB, Young MD, Mason RJ, Ambrosino DM, Wentworth DE, Demartini JC, and Holmes KV. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 101: 15748-15753, 2004.
93. Jessop CE, Chakravarthi S, Watkins RH, and Bulleid NJ. Oxidative protein folding in the mammalian endoplasmic reticulum. Biochem Soc Trans 32: 655-658, 2004.
94. Jiang XM, Fitzgerald M, Grant CM, and Hogg PJ. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. J Biol Chem 214: 2416-2423, 1999.
95. Jolly C, Kashefi K, Hollinshead M, and Sattentau, QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 199: 283-293, 2004.
96. Kampmann T, Mueller DS, Mark AE, Young PR, and Kobe B. The role of histidine residues in low-pH-mediated viral membrane fusion. Structure 14:1481-1487, 2006.
97. Kan B, Wang M, Jing H, Xu H, Jiang X, Yan M, Liang W, Zheng H, Wan K, Liu Q, Cui B, Xu Y, Zhang E, Wang H, Ye J, Li G, Li M, Cui Z, Qi X, Chen K, Du L, Gao K, Zhao YT, Zou XZ, Feng YJ, Gao YF, Hai R, Yu D, Guan Y, and Xu J. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol 79: 11892-11900, 2005
98. Kao RY, Tsui WH, Lee TS, Tanner JA, Watt RM, Huang JD, Hu L, Chen G, Chen Z, Zhang L, He T, Chan KH, Tse H, To AP, Ng LW, Wong BC, Tsoi HW, Yang D, Ho DD, and Yuen KY. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol 11: 1293-1299, 2004.
99. Kemmink J, Darby NJ, Dijkstra K, Nilges M, and Creighton TE. The folding catalyst protein disulfide isomerase is constructed of active and inactive thioredoxin modules. Curr Biol 7: 239-245, 1997.
100. Kido H, Fukutomi A, and Katunuma N. Tryptase TL2 in the membrane of human T4+ lymphocytes is a novel binding protein of the V3 domain of HIV-1 envelope glycoprotein gp120. FEBS Lett 286: 233-236, 1991.
101. Klappa P, Ruddock LW, Darby NJ, and Freedman RB. The b0 domain provides the principal peptide-binding site of protein disulfide isomerase but all domains contribute to binding of misfolded proteins. EMBO J 17: 927-935, 1998.
102. Krey T, Thiel HJ, and Rümenapf T. Acid-resistant bovine pestivirus requires activation for pH-triggered fusion during entry J Virol 19: 4191-4200, 2005.
103. Kroning H, Kahne T, Ittensson A, Franke A, and Ansorge S. Thiol-protein disulfide-oxidoreductase protein disulfide isomerase: a new plasma membrane constituent of mature human B lymphocytes. Scand J Immunol 39: 346-350, 1994.
104. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, Stohr K, Peiris JS, and Osterhaus AD. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome Lancet 362: 263-270, 2003.
105. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (Lond) 393: 648-659, 1998.
106. Laboissiere MCA, Sturley SL, and Raines RT. The essential function of protein disulfide isomerase is to unscramble non-native disulfide bonds. J Biol Chem 270: 28006-28009, 1995.
107. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, and Burton DR. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77: 10557-10565, 2003.
108. Lahav J, Jurk K, Hess O, Barnes MJ, Frandale RW, Luboshitz J, and Kehrel BE. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 100: 2472-2478, 2002.
109. Lai MM and Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res 48: 1-100, 1997.
110. Lai MMC and Holmes KV. Coronaviridae: the viruses and their replication. In: Fields Virology, edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wilkins, 2001, pp. 1163-1203.
111. Lammert E, Stevanovi S, Brunner J, Rammensee HG, and Schild H. Protein disulfide isomerase is the dominant acceptor for peptides translocated into the endoplasmic reticulum. Eur J Immunol 27: 1685-1690, 1997.
112. Lavillette D, Barbouche R, Yao Y, Boson B, Cosset FL, Jones IM, and Fenouillet E. Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein: comparison with HIV Env. J Biol Chem 281: 9200-9204, 2006.
113. Lawrence DA, Song R, and Weber P. Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation. J Leukoc Biol 60: 611-618, 1996.
114. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak Jr M, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, and Hartley O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306: 485-487, 2004.
115. Leonard C, Spellman MW, Riddle L, Harris R, Thomas J, and Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382, 1990.
116. Li F, Li W, Farzan M, and Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309: 1864-1868, 2005.
117. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, and Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (Lond) 426: 450-454, 2003.
118. Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, and Farzan M. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24: 1634-1643, 2005.
119. Li W, Wong SK, Li F, Kuhn JH, Huang IC, Choe H, and Farzan M. Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol 80: 4211-4219, 2006.
120. Liang PH. Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem 6: 361-376. 2006
121. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, and Colonno R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A 100, 11013-11018, 2003.
122. Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A, and Bankston LA. Cysteine regulation of protein function as exemplified by NMDA-receptor modulation. Trends Neurosci 25: 474-480, 2002.
123. Liu H, Hwangbo Y, Holte S, Lee J, Wang C, Kaupp N, Zhu H, Celum C, Corey L, McElrath MJ, and Zhu T. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecules-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 190:1055-1058, 2004.
124. Locker JK and Griffiths G. An unconventional role for cytoplasmic disulfide bonds in vaccinia virus proteins. J Cell Biol 144: 267-279, 1999.
125. Lusso P. HIV and the chemokine system: 10 years later. EMBO J 25: 447-455, 2006.
126. Lyles MM and Gilbert HF. Mutations in the thioredoxin sites of protein disulfide isomerase reveal functional nonequivalence of the N- and C-terminal domains. J Biol Chem 269: 30946-30952, 1994.
127. Madani N, Perdigoto AL, Srinivasan K, Cox JM, Chruma JJ, LaLonde J, Head M, Smith AB 3rd, and Sodroski JG. Localized changes in gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitor BMS-806 and 155. J Virol 78: 3742-3752, 2004.
128. Maerz AL, Center RJ, Kemp BE, Kobe B, and Poumbourios P. Functional implications of the human T-lymphotropic virus type 1 transmembrane glycoprotein helical hairpin structure. J Virol 74: 6614-6621, 2000.
129. Maerz AL, Drummer HE, Wilson KA, and Pombourios P. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association. J Virol 75: 6635-6644, 2001.
130. Mandel R, Ryser HJ, Ghani F, Wu M, and Peak D. Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase. Proc Natl Acad Sci U S A 90: 4112-4116, 1993.
131. Markosyan RM, Cohen FS, and Melikyan GB. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell 14: 926-938, 2003.
132. Markosyan RM, Melikyan GB, and Cohen FS. Evolution of intermediates of influenza virus hemagglutinin mediated fusion revealed by kinetic measurements of pore formation. Biophys J 80: 812-821, 2001.
133. Markovic I and Clouse KA. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2: 223-234, 2004.
134. Markovic I, Pulyaeva H, Sokoloff A, and Chernomordik LV. Membrane fusion mediated by baculovirus gp64 involves assembly of stable gp64 trimers into multiprotein aggregates. J Cell Biol 143: 1155-1166, 1998.
135. Markovic I, Stantchev TS, Fields KH, Tiffany LJ, Tomic M, Weiss CD, Broder CC, Strebel K, and Clouse KA. Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood 103: 1586-1594, 2004.
136. Martin L, Stricher F, Misse D, Sironi F, Pugniere M, Barthe P, Prado-Gotor R, Freulon I, Magne X, Roumestand C, Menez A, Lusso P, Veas F, and Vita C. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 21: 71-76, 2003.
137. Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, Peiris JS, Lim W, and Osterhaus AD. Virology: SARS virus infection of cats and ferrets. Nature (Lond) 425: 915, 2003.
138. Matthias LJ and Hogg PJ. Redox control on the cell surface: implications for HIV-1 entry. Antioxid Redox Signal 5: 133-138, 2003.
139. Matthias LJ, Yam PT, Jiang XM, Vandegraaff N, Li P, Poumbourios P, Donoghue N, and Hogg PJ. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol 3: 727-732, 2002.
140. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, and Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151: 413-423, 2000.
141. Mills SG and DeMartino JA. Chemokine receptor-directed agents as novel anti-HIV-1 therapies. Curr Top Med Chem 4:1017-1330, 2004.
142. Mondor I, Ugolini S, and Sattentau QJ. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4-independent and gp120 dependent and requires cell surface heparans. J Virol 72: 3623-3634, 1998.
143. Moore JP and Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A 100: 10598-10602, 2003.
144. Moore JP and Klasse PJ. Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation. AIDS Res Hum Retroviruses 8: 443-450, 1992.
145. Moore MJ, Dorfman T, Li W, Wong SK, Li Y, Kuhn JH, Coderre J, Vasilieva N, Han Z, Greenough TC, Farzan M, and Choe H. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol 78: 10628-10635, 2004.
146. Mothes W, Boerger AL, Narayan S, Cunningham JM, and Young JA. Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell 103: 679-689, 2000.
147. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao J, Olson W, Kwong PD, and Sattentau QJ. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 74: 1948-1960, 2000.
148. Nakamura H. Thioredoxin and its related molecules: update 2005. Antioxid Redox Signal 2005 7: 823-828.
149. Neuman BW, Adair BD, Yoshioka C, Quispe JD, Milligan RA, Yeager M, and Buchmeier MJ. Ultrastructure of SARS-CoV, FIPV, and MHV revealed by electron cryomicroscopy. Adv Exp Med Biol 581: 181-185, 2006.
150. Ng ML, Tan SH, See EE, Ooi EE, and Ling AE. Early events of SARS coronavirus infection in vero cells. J Med Virol 71: 323-331, 2003.